Identity of the T cell antigen receptor revealed
1991-1992
CTLA-4 is the second B7 ligand
2000-2002
PD-1/PD-L1 regulates T cell activation
2010
Anti-CTLA-4 improves survival in patients with advanced melanoma A turning point in the clinical trials using checkpoint inhibitors to treat cancer was the publication of a multicentric study documenting improved survival in patients with metastatic melanoma treated with anti-CTLA-4. These results prompted the approval of ipilimumab, an anti-CTLA-4 antibody, by the FDA in the following year.
1994-1995
CTLA-4 is a negative regulator of T cell activation T cell activation by "signal one" is modulated not only by positive costimulatory signals but by negative regulating molecules as well, laying the ground for the idea of an inhibitory checkpoint. In 1996, animal experiments provided the proof of concept that blocking the inhibitory checkpoint improves antitumor responses.
1987-1988
T cell activation requires two signals "Seeing" antigen is not enough to activate T lymphocytes. A second signal, provided by an "accessory" cell, is required to unleash T cell effector function.
B7 is the CD28 ligand in APCs

2005-2006
PD-1 blockade reverses T cell exhaustion PD-1 had been identi ed and cloned long ago, but only in the early 2000s was its role in T cell activation and immune exhaustion uncovered.
2015
>150 clinical trials using checkpoint blockade in multiple types of cancer 
